(DAW-noh-ROO-bih-sin HY-droh-KLOR-ide … sy-TAYR-uh-been LY-poh-some)
This page contains brief information about daunorubicin hydrochloride and cytarabine liposome and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Daunorubicin hydrochloride and cytarabine liposome is approved to treat:
- Acute myeloid leukemia (AML) that is newly diagnosed. It is used in adults with therapy-related AML (tAML) or AML with myelodysplasia-related changes (AML-MRC).
Daunorubicin hydrochloride and cytarabine liposome is a combination form of daunorubicin hydrochloride and cytarabine contained inside liposomes (very tiny particles of fat). This form may work better than other forms of these drugs and have fewer side effects. Also, because its effects last longer in the body, it doesn’t need to be given as often. For more information about daunorubicin hydrochloride and cytarabine that may apply to this combination drug, see the Drug Information Summaries for Daunorubicin Hydrochloride and Cytarabine.
Daunorubicin hydrochloride and cytarabine liposome is also being studied in the treatment of other types of cancer.
More About Daunorubicin Hydrochloride and Cytarabine Liposome
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Daunorubicin Hydrochloride and Cytarabine Liposome – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Liposome-encapsulated Daunorubicin-cytarabine – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
